Navigation Links
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Date:2/27/2009

CUPERTINO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that Endo Pharmaceuticals (Nasdaq: ENDP) has given notice that it is returning to us Endo's rights in the U.S. and Canada to develop and commercialize TRANSDUR(TM)-Sufentanil, a proprietary transdermal patch in development intended to treat chronic pain. Endo and DURECT recently completed a successful end-of-Phase II meeting with the FDA. Endo has notified us of its intention to terminate the license agreement entered into between Endo and DURECT, and has committed to assist in an orderly and rapid transition of this program back to DURECT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"We are disappointed to lose Endo as a partner for the U.S. and Canada, but understand that the program is no longer a strategic fit for them," stated James Brown, President and CEO of DURECT. "However, we appreciate the fact that Endo substantially advanced this program such that it is now Phase III ready. With the worldwide rights to this program restored to us, we believe we have an attractive asset to partner or to progress it ourselves."

Endo recently successfully completed a Phase II program for TRANSDUR- Sufentanil in which they evaluated the conversion of patients on oral and transdermal opioids to TRANSDUR-Sufentanil. The most recent Phase II study met its primary and secondary objectives of establishing a successful dose- titration regimen and dose potency relationships, demonstrating safety and tolerability at the therapeutic dose, and achieving effective analgesic pain control. The Phase II data, extensive non-clinic
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... In recognition of Veteran’s Day, Discount Labels ... a local organization that provides services to veterans and ... on a couple hundred acres in the hills of ... class fishing, hunting, hiking, horseback riding, 4-wheeling, skeet shooting, ... ago to support U.S. Service men and women, police ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... December 22, 2014 7,178 small business ... of Black Friday shopping and opted instead to join ... education company, for their 5th annual “Black Friday Boot ... just $7 to attend the 5 hour online training ... promptly donated to support two Central Texas based charities ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 Luxury Linen ... Community Partners of Dallas to provide logistics and ... Dallas-based company, Peacock Alley has a long history of giving ... The additional sponsors of this year's Toy Drive were Whataburger® ... to give back than the holidays. Providing gifts to children ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. Ms. Foley is recognized with ... largest, most-recognized networking organization of professional women in the ... Association of Professional Women is a powerfully vibrant networking ... Chapters. , “As a nurse, I felt like I ...
Breaking Medicine News(10 mins):Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2
... , IRVINE, Calif., July 21 Masimo ... and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced the ... System, a revolutionary new sensor system that offers the performance ... cost-effectiveness and environmentally-green advantages of a reusable sensor. The new ...
... PHOENIX, July 21 What do moving and health have in ... to helping women has selected House to Home Services, LLC, a moving company ... , , , ... Janice Montana, president and CEO, House to Home Services, LLC.) , ...
... LEE, N.J., July 21 The Neutraceutical Company, LLC (TNC -- ... agreement for exclusive rights to direct market a remarkable new extract ... in multiple ways for centuries. This new, 100% natural product is ... aimed at helping people cope with everyday health concerns. , ...
... , OKLAHOMA CITY, July 21 ... been selected by R&D Magazine to receive the 2009 ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090721/DA49239 ) , ... in the fitting and ongoing management of prosthetic device users. This ...
... , , , MONROVIA, ... a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today ... Administration (FDA) Division of Bioresearch Monitoring that the restrictions of the "integrity ... been removed. The removal of the integrity hold enables the FDA ...
... , , MINEOLA, N.Y., July 21 ... rebranding operation to better represent the organization while educating about the ... , The new marketing material and ... is in Your Hands" pertaining to taking an active stance in ...
Cached Medicine News:Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 2Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 3Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 4Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 5Health News:House to Home Services is Selected as a Unique Health Provider 2Health News:The Neutraceutical Company Announces Powerful New 'Feel-Good' Product 2Health News:Orthocare Innovations Receives Prestigious R&D 100 Award for Computerized Prosthesis Alignment System 2Health News:Orthocare Innovations Receives Prestigious R&D 100 Award for Computerized Prosthesis Alignment System 3Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 2Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 3Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 4Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 5Health News:The Maurer Foundation for Breast Health Education Launches Integrated Rebranding Operation 2
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
(Date:12/19/2014)... Friday, December 19 edition of USA ... features Konica Minolta, the company announced today. The supplement will focus ... organizations. In addition to the print section that ... New York , Chicago , ... Minneapolis and San Francisco , a ...
(Date:12/19/2014)... , Dec. 19, 2014  Newport Corporation (NASDAQ: ... Kadia, Ph.D. has joined the company,s Board of ... Officer and a director of Evans Analytical Group, ... evaluation and analytical services to companies in a ... to joining Evans Analytical Group, Dr. Kadia spent ...
Breaking Medicine Technology:Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... (gadopentetate dimeglumine) injection was introduced in 1988, ... contrast-enhanced magnetic resonance imaging (MRI). It became ... in MRI. Today, the product is still ... head, neck and body. MAGNEVIST is used ...
... injection is a nonionic, iodinated, low-osmolar ... Introduced in the U.S. in 1995, ... Europe, ULTRAVIST today is used ... established a positive clinical experience in ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Forceps with round handle, straight...
Medicine Products: